<trans-title xml:lang="en"/>_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

¹ , ² ,  ¹

1. ;
2. ;

Corresponding?author：

, Email: hy_zhang@scu.edu.cn

Keywords：

DOI：

10.7507/1007-9424.201702005

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 陳卉嬌, 張波, 張紅英. . CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2017, 24(2): 163-168. doi: 10.7507/1007-9424.201702005 Copy

1.	?Fletcher CD, Bridge JA, Hogendoorm PC,et al. World Health Organization classification of soft tissue and bone tumours. 4th ed. Lyon: IARC Press, 2013: 164-167.
2.	National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: soft tissue sarcoma, version 1 [Internet]. Fort Washington, PA: National Comprehensive Cancer Network; 2017 [cited 2017 Jun 15]. Available from: http://www.nccn.org/ professionals/physician_gls/pdf/sarcoma.pdf.
3.	ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2014, 25 Suppl 3: iii21-iii6.
4.	Koo DH, Ryu MH, Kim KM,et al. Asian Consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor. Cancer Res Treat, 2016, 48(4): 1155-1166.
5.	中國 CSCO 胃腸間質瘤專家委員會. 中國胃腸間質瘤診斷治療共識 (2013 年版). 中華胃腸外科雜志, 2014, 17(4): 393-398.
6.	Fletcher CD, Berman JJ, Corless C,et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol, 2002, 33(5): 459-465.
7.	Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol, 2006, 23(2): 70-83.
8.	Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol, 2008, 39(10): 1411-1419.
9.	Joensuu H, Vehtari A, Riihim?ki J,et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol, 2012, 13(3): 265-274.
10.	Agaimy A. Gastrointestinal stromal tumors (GIST) from risk stratification systems to the new TNM proposal: more questions than answers? A review emphasizing the need for a standardized GIST reporting. Int J Clin Exp Pathol, 2010, 3(5): 461-471.
11.	Hirota S, Isozaki K, Moriyama Y,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 1998, 279(5350): 577-580.
12.	Kindblom LG, Remotti HE, Aldenborg F,et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol, 1998, 152(5): 1259-1269.
13.	虞積耀, 崔全才主譯. 胃腫瘤—胃間葉性腫瘤//世界衛生組織腫瘤分類及診斷標準系列：消化系統腫瘤病理學和遺傳學. 北京：人民衛生出版社, 2006: 39-79.
14.	Appelman HD. Mesenchymal tumors of the gut: historical perspectives, new approaches, new results, and does it make any difference? Monogr Pathol, 1990, (31): 220-246.
15.	de Saint Aubain Somerhausen N, Fletcher CD. Gastrointestinal stromal tumours: An update. Sarcoma, 1998, 2: 133-141.
16.	DeMatteo RP, Lewis JJ, Leung D,et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg, 2000, 231(1): 51-58.
17.	Ranchod M, Kempson RL. Smooth muscle tumors of the gastrointestinal tract and retroperitoneum: a pathologic analysis of 100 cases. Cancer, 1977, 39(1): 255-262.
18.	Evans HL. Smooth muscle tumors of the gastrointestinal tract. A study of 56 cases followed for a minimum of 10 years. Cancer, 1985, 56(9): 2242-2250.
19.	Miettinen M, Lasota J. Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch, 2001, 438(1): 1-12.
20.	Miettinen M, Sarlomo-Rikala M, Sobin LH,et al. Esophageal stromal tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas. Am J Surg Pathol, 2000, 24(2): 211-222.
21.	Miettinen M, Makhlouf H, Sobin LH,et al. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol, 2006, 30(4): 477-489.
22.	Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1 765 cases with long-term follow-up. Am J Surg Pathol, 2005, 29(1): 52-68.
23.	Miettinen M, Kopczynski J, Makhlouf 3rd HR,et al. Gastrointestinal stromal tumors, intramural leiomyomas and leiomyosarcomas in the duodenum—A clinicopathologic, immunohistochemical and molecular genetic study of 167 cases. Am J Surg Pathol, 2003, 27(5): 625-641.
24.	Miettinen M, Furlong M, Sarlomo-Rikala M,et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol, 2001, 25(9): 1121-1133.
25.	Miettinen M, Monihan JM, Sarlomo-Rikala M,et al. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol, 1999, 23(9): 1109-1118.
26.	張森麗. 如何計算顯微鏡下視野面積. 診斷病理學雜志, 2009, 16(1): 79.
27.	Fred TB, Fatima C, Ralph HH,et al. WHO classification of tumors of the digestive system. 4th ed. Lyon: IARC Press, 2010: 74-76.
28.	Rubin BP, Blanke CD, Demetri GD,et al. Protocol for the examination of specimens from patients with gastrointestinal stromal tumor. Arch Pathol Lab Med, 2010, 134(2): 165-170.
29.	Gastrointestinal Stromal Tumors Treatment (PDQ?)–Health Professional Version. https://www.cancer.gov/types/soft-tissue-sarcoma/hp/gist-treatment-pdq.
30.	Joensuu H, Roberts PJ, Sarlomo-Rikala M,et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med, 2001, 344(14): 1052-1056.
31.	Dematteo RP, Gold JS, Saran L,et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer, 2008, 112(3): 608-615.
32.	Ryu MH, Kang YK, Jang SJ,et al. Prognostic significance of p53 gene mutations and protein overexpression in localized gastrointestinal stromal tumours. Histopathology, 2007, 51(3): 379-389.
33.	Tryggvason G, Gíslason HG, Magnússon MK,et al. Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer, 2005, 117(2): 289-293.
34.	Takahashi T, Nakajima K, Nishitani A,et al. An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors. Int J Clin Oncol, 2007, 12(5): 369-374.
35.	Rutkowski P, Nowecki ZI, Michej W,et al. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol, 2007, 14(7): 2018-2027.
36.	Mucciarini C, Rossi G, Bertolini F,et al. Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. BMC Cancer, 2007, 7: 230.
37.	Nilsson B, Bümming P, Meis-Kindblom JM,et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—a population-based study in western Sweden. Cancer, 2005, 103(4): 821-829.
38.	Huang HY, Li CF, Huang WW,et al. A modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: a subdivision of the original high-risk group on the basis of outcome. Surgery, 2007, 141(6): 748-756.
39.	Hassan I, You YN, Shyyan R,et al. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann Surg Oncol, 2008, 15(1): 52-59.
40.	Rutkowski P, Bylina E, Wozniak A,et al. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour—the impact of tumour rupture on patient outcomes. Eur J Surg Oncol, 2011, 37(10): 890-896.
41.	Yanagimoto Y, Takahashi T, Muguruma K,et al. Re-appraisal of risk classifications for primary gastrointestinal stromal tumors (GISTs) after complete resection: indications for adjuvant therapy. Gastric Cancer, 2015, 18(2): 426-433.
42.	Steigen SE, Eide TJ, Wasag B,et al. Mutations in gastrointestinal stromal tumors—a population-based study from Northern Norway. APMIS, 2007, 115(4): 289-298.
43.	Mazzola P, Spitale A, Banfi S,et al. Epidemiology and molecular biology of gastrointestinal stromal tumors (GISTs): a population-based study in the South of Switzerland, 1999-2005. Histol Histopathol, 2008, 23(11): 1379-1386.
44.	Braconi C, Bracci R, Bearzi I,et al. KIT and PDGFRalpha mutations in 104 patients with gastrointestinal stromal tumors (GISTs): a population-based study. Ann Oncol, 2008, 19(4): 706-710.
45.	Brabec P, Sufliarsky J, Linke Z,et al. A whole population study of gastrointestinal stromal tumors in the Czech Republic and Slovakia. Neoplasma, 2009, 56(5): 459-464.
46.	Rossi S, Miceli R, Messerini L,et al. Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am J Surg Pathol, 2011, 35(11): 1646-1656.
47.	粱小波. 可切除胃腸間質瘤的術后風險評估標準及其評價. 中華胃腸外科雜志, 2013, 16(3): 205-207.
48.	汪明, 曹暉. 胃腸間質瘤危險度評估方法的再認識. 中華胃腸外科雜志, 2015, 18(4): 309-312.

1. ?Fletcher CD, Bridge JA, Hogendoorm PC,et al. World Health Organization classification of soft tissue and bone tumours. 4th ed. Lyon: IARC Press, 2013: 164-167.
2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: soft tissue sarcoma, version 1 [Internet]. Fort Washington, PA: National Comprehensive Cancer Network; 2017 [cited 2017 Jun 15]. Available from: http://www.nccn.org/ professionals/physician_gls/pdf/sarcoma.pdf.
3. ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2014, 25 Suppl 3: iii21-iii6.
4. Koo DH, Ryu MH, Kim KM,et al. Asian Consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor. Cancer Res Treat, 2016, 48(4): 1155-1166.
5. 中國 CSCO 胃腸間質瘤專家委員會. 中國胃腸間質瘤診斷治療共識 (2013 年版). 中華胃腸外科雜志, 2014, 17(4): 393-398.
6. Fletcher CD, Berman JJ, Corless C,et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol, 2002, 33(5): 459-465.
7. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol, 2006, 23(2): 70-83.
8. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol, 2008, 39(10): 1411-1419.
9. Joensuu H, Vehtari A, Riihim?ki J,et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol, 2012, 13(3): 265-274.
10. Agaimy A. Gastrointestinal stromal tumors (GIST) from risk stratification systems to the new TNM proposal: more questions than answers? A review emphasizing the need for a standardized GIST reporting. Int J Clin Exp Pathol, 2010, 3(5): 461-471.
11. Hirota S, Isozaki K, Moriyama Y,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 1998, 279(5350): 577-580.
12. Kindblom LG, Remotti HE, Aldenborg F,et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol, 1998, 152(5): 1259-1269.
13. 虞積耀, 崔全才主譯. 胃腫瘤—胃間葉性腫瘤//世界衛生組織腫瘤分類及診斷標準系列：消化系統腫瘤病理學和遺傳學. 北京：人民衛生出版社, 2006: 39-79.
14. Appelman HD. Mesenchymal tumors of the gut: historical perspectives, new approaches, new results, and does it make any difference? Monogr Pathol, 1990, (31): 220-246.
15. de Saint Aubain Somerhausen N, Fletcher CD. Gastrointestinal stromal tumours: An update. Sarcoma, 1998, 2: 133-141.
16. DeMatteo RP, Lewis JJ, Leung D,et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg, 2000, 231(1): 51-58.
17. Ranchod M, Kempson RL. Smooth muscle tumors of the gastrointestinal tract and retroperitoneum: a pathologic analysis of 100 cases. Cancer, 1977, 39(1): 255-262.
18. Evans HL. Smooth muscle tumors of the gastrointestinal tract. A study of 56 cases followed for a minimum of 10 years. Cancer, 1985, 56(9): 2242-2250.
19. Miettinen M, Lasota J. Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch, 2001, 438(1): 1-12.
20. Miettinen M, Sarlomo-Rikala M, Sobin LH,et al. Esophageal stromal tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas. Am J Surg Pathol, 2000, 24(2): 211-222.
21. Miettinen M, Makhlouf H, Sobin LH,et al. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol, 2006, 30(4): 477-489.
22. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1 765 cases with long-term follow-up. Am J Surg Pathol, 2005, 29(1): 52-68.
23. Miettinen M, Kopczynski J, Makhlouf 3rd HR,et al. Gastrointestinal stromal tumors, intramural leiomyomas and leiomyosarcomas in the duodenum—A clinicopathologic, immunohistochemical and molecular genetic study of 167 cases. Am J Surg Pathol, 2003, 27(5): 625-641.
24. Miettinen M, Furlong M, Sarlomo-Rikala M,et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol, 2001, 25(9): 1121-1133.
25. Miettinen M, Monihan JM, Sarlomo-Rikala M,et al. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol, 1999, 23(9): 1109-1118.
26. 張森麗. 如何計算顯微鏡下視野面積. 診斷病理學雜志, 2009, 16(1): 79.
27. Fred TB, Fatima C, Ralph HH,et al. WHO classification of tumors of the digestive system. 4th ed. Lyon: IARC Press, 2010: 74-76.
28. Rubin BP, Blanke CD, Demetri GD,et al. Protocol for the examination of specimens from patients with gastrointestinal stromal tumor. Arch Pathol Lab Med, 2010, 134(2): 165-170.
29. Gastrointestinal Stromal Tumors Treatment (PDQ?)–Health Professional Version. https://www.cancer.gov/types/soft-tissue-sarcoma/hp/gist-treatment-pdq.
30. Joensuu H, Roberts PJ, Sarlomo-Rikala M,et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med, 2001, 344(14): 1052-1056.
31. Dematteo RP, Gold JS, Saran L,et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer, 2008, 112(3): 608-615.
32. Ryu MH, Kang YK, Jang SJ,et al. Prognostic significance of p53 gene mutations and protein overexpression in localized gastrointestinal stromal tumours. Histopathology, 2007, 51(3): 379-389.
33. Tryggvason G, Gíslason HG, Magnússon MK,et al. Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer, 2005, 117(2): 289-293.
34. Takahashi T, Nakajima K, Nishitani A,et al. An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors. Int J Clin Oncol, 2007, 12(5): 369-374.
35. Rutkowski P, Nowecki ZI, Michej W,et al. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol, 2007, 14(7): 2018-2027.
36. Mucciarini C, Rossi G, Bertolini F,et al. Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. BMC Cancer, 2007, 7: 230.
37. Nilsson B, Bümming P, Meis-Kindblom JM,et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—a population-based study in western Sweden. Cancer, 2005, 103(4): 821-829.
38. Huang HY, Li CF, Huang WW,et al. A modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: a subdivision of the original high-risk group on the basis of outcome. Surgery, 2007, 141(6): 748-756.
39. Hassan I, You YN, Shyyan R,et al. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann Surg Oncol, 2008, 15(1): 52-59.
40. Rutkowski P, Bylina E, Wozniak A,et al. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour—the impact of tumour rupture on patient outcomes. Eur J Surg Oncol, 2011, 37(10): 890-896.
41. Yanagimoto Y, Takahashi T, Muguruma K,et al. Re-appraisal of risk classifications for primary gastrointestinal stromal tumors (GISTs) after complete resection: indications for adjuvant therapy. Gastric Cancer, 2015, 18(2): 426-433.
42. Steigen SE, Eide TJ, Wasag B,et al. Mutations in gastrointestinal stromal tumors—a population-based study from Northern Norway. APMIS, 2007, 115(4): 289-298.
43. Mazzola P, Spitale A, Banfi S,et al. Epidemiology and molecular biology of gastrointestinal stromal tumors (GISTs): a population-based study in the South of Switzerland, 1999-2005. Histol Histopathol, 2008, 23(11): 1379-1386.
44. Braconi C, Bracci R, Bearzi I,et al. KIT and PDGFRalpha mutations in 104 patients with gastrointestinal stromal tumors (GISTs): a population-based study. Ann Oncol, 2008, 19(4): 706-710.
45. Brabec P, Sufliarsky J, Linke Z,et al. A whole population study of gastrointestinal stromal tumors in the Czech Republic and Slovakia. Neoplasma, 2009, 56(5): 459-464.
46. Rossi S, Miceli R, Messerini L,et al. Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am J Surg Pathol, 2011, 35(11): 1646-1656.
47. 粱小波. 可切除胃腸間質瘤的術后風險評估標準及其評價. 中華胃腸外科雜志, 2013, 16(3): 205-207.
48. 汪明, 曹暉. 胃腸間質瘤危險度評估方法的再認識. 中華胃腸外科雜志, 2015, 18(4): 309-312.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content